TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03342196
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.~Melphalan may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash.
Study: NCT03342196
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.~Thiotepa may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash.
Study: NCT03342196
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine is an antineoplastic fluorinated nucleoside analog and inhibits DNA synthesis through inhibition of polymoerase alpha after incorporation into DNA.~Fludarabine may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash, and lower limb weakness.
Study: NCT02486510
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.~Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours
Study: NCT04056455
Drug: Mobocertinib
Normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobocertinib capsule.
Study: NCT01580592
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150mg, s.c., every 4 weeks
Study: NCT01580592
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300mg, s.c., every 4 weeks
Study: NCT03308084
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure
Study: NCT03308084
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of 10mg Dexamethasone IV intraoperatively
Study: NCT00004993
Drug: Parathyroid hormone (hPTH 1-34)
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02784210
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 days of corticosteroids (intravenous methylprednisolone at 1000 mg/day
Study: NCT02784210
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 days of corticosteroids (oral prednisone at 1250 mg/day
Study: NCT01107756
Drug: LENOGRASTIM (GRANOGYTE 34)
Normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert
Study: NCT04322565
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cochicine 1mg/day
Study: NCT00715611
Drug: pemetrexed and cisplatin or carboplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.
Study: NCT01404130
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5-1mg/kg daily for 4-6 months
Study: NCT02605447
Drug: 3 months of dual antiplatelet therapy (DAPT)
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
Study: NCT00235651
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00158548
Drug: SP, chloroquine, amodiaquine, primaquine, artesunate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02296996
Drug: Dabrafenib + Trametinib
Normalized name: Dabrafenib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01232894
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol 150 µg once-daily via single-dose dry powder inhaler
Study: NCT03701308
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03701308
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03701308
Drug: Uproleselan
Normalized name: Uproleselan
DrugBank: Uproleselan (DB14829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02693535
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: drug
Study: NCT02693535
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: drug
Study: NCT02693535
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: drug
Study: NCT02693535
Drug: Trastuzumab and Pertuzumab
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: drug
Study: NCT02693535
Drug: Vemurafenib and Cobimetinib
Normalized name: Vemurafenib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: drug
Study: NCT02693535
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: drug
Study: NCT02693535
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: drug
Study: NCT02693535
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: drug
Study: NCT02693535
Drug: Nivolumab and Ipilimumab
Normalized name: nivolumab and relatlimab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: drug
Study: NCT02693535
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: drug
Study: NCT02693535
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug
Study: NCT02693535
Drug: Atezolizumab and PHESGO
Normalized name: Phesgo
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: drug
Study: NCT02693535
Drug: Atezolizumab and Talazoparib
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: drug
Study: NCT02693535
Drug: Entrectinib
Normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: drug
Study: NCT02693535
Drug: Larotrectinib
Normalized name: Larotrectinib
DrugBank: Larotrectinib (DB14723)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: drug
Study: NCT02693535
Drug: Tucatinib plus Trastuzumab Subcutaneous (SC)
Normalized name: tucatinib
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: drug
Study: NCT02693535
Drug: Futibatinib
Normalized name: Futibatinib
DrugBank: Futibatinib (DB15149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug
Study: NCT03260491
Drug: HER3-DXd (FL-DP)
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER3-DXd (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).
Study: NCT03260491
Drug: HER3-DXd (CTM-1 Lyo-DP)
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.
Study: NCT03260491
Drug: HER3-DXd (CTM-3 Lyo-DP)
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
DrugBank: Zenocutuzumab (DB15559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the commercial manufacturing sites.
Study: NCT00610727
Drug: Prochlorperazine 0.5 mg IV over 5 sec
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Prochlorperazine for bioavailability
Study: NCT00610727
Drug: Inhaled prochlorperazine 5 mg
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: InhaledStaccato Prochlorperazine 5 mg
Study: NCT00610727
Drug: Inhaled prochlorperazine 10 mg
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: InhaledStaccato Prochlorperazine 10 mg
Study: NCT00610727
Drug: Prochlorperazine 10 mg IV over 5 sec
Normalized name: prochlorperazine 10 MG
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prochlorperazine 10 mg IV over 5 sec for patient qualification
Study: NCT03348735
Drug: Lidocaine patch 5%
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of Lidocaine 5% patch for 12 hours.
Study: NCT03348735
Drug: Capsaicin 8% Patch
Normalized name: CAPSAICIN 8% PATCH KIT,4
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of Capsaicin 8% patch for
Study: NCT03348735
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe.
Study: NCT02871219
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02465060
Drug: Adavosertib
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Afatinib Dimaleate
Normalized name: afatinib dimaleate
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02465060
Drug: Capivasertib
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02465060
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02465060
Drug: Dabrafenib Mesylate
Normalized name: dabrafenib mesylate
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02465060
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Defactinib
Normalized name: Defactinib
DrugBank: Defactinib (DB12282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Defactinib Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Defactinib (DB12282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Erdafitinib
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03289273
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As per the treating physicians discretion
Study: NCT02465060
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Larotrectinib
Normalized name: Larotrectinib
DrugBank: Larotrectinib (DB14723)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02465060
Drug: Larotrectinib Sulfate
Normalized name: Larotrectinib sulfate
DrugBank: Larotrectinib (DB14723)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02465060
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02465060
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02465060
Drug: PI3K-beta Inhibitor GSK2636771
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Sapanisertib
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Sunitinib Malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Taselisib
Normalized name: Taselisib
DrugBank: Taselisib (DB12108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02465060
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02465060
Drug: Ulixertinib
Normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Give PO
Study: NCT02465060
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01327651
Drug: Event-driven dosing
Normalized name: romosozumab
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TDF/FTC as needed with a post exposure dose
Study: NCT04069156
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to either Placebo or Aspirin post implant.
Study: NCT01994291
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Injection supplied as:~* 10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.~* 6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.~* Adminstered once a month for 12 weeks
Study: NCT01994291
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 50mg tablets PF-04634817 once a day for 12 weeks.
Study: NCT01577589
Drug: 600 mg ceftaroline fosamil in 50 ml infusion volume
Normalized name: ceftaroline fosamil 600 MG
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01577589
Drug: 600 ceftaroline fosamil in 250 ml infusion volume
Normalized name: ceftaroline fosamil 600 MG
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01577589
Drug: 600 mg ceftaroline in 100 ml infusion volume
Normalized name: ceftaroline fosamil 600 MG
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT02305160
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
Study: NCT00451048
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT02046486
Drug: Ticagrelor 180mg whole tablets
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02046486
Drug: Ticagrelor 180mg crushed and dispersed
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00026299
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00237653
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03270878
Drug: Glasdegib Oral Tablet
Normalized name: glasdegib Oral Tablet
DrugBank: Glasdegib (DB11978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
Study: NCT03270878
Drug: Glasdegib IV infusion
DrugBank: Glasdegib (DB11978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
Study: NCT00408083
Drug: MultiHance
Normalized name: Multihance
DrugBank: Gadobenic acid (DB00743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mmol/kg as a single dose administration
Study: NCT00408083
Drug: Magnevist
Normalized name: Magnevist
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mmol/kg as a single dose administration
Study: NCT04140162
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: 16 mg/kg actual body weight IV weekly (weeks 1-8; total of 8 doses) then every 2 weeks (weeks 9-24; total of 8 doses).~Consolidation: 16 mg/kg actual body weight IV every four weeks (weeks 25-36)~Maintenance: 16 mg/kg actual body weight IV every eight weeks (weeks 37-88)~Sites will continue to use IV daratumumab to treat existing study patients until the IV daratumumab stock on site has been exhausted. The sites will then transition existing patient to SQ daratumumab. New patients will be started on SQ 1800mg daratumumab.~Induction- Cycles 1-2 (days 1, 8,15, 22), Cycles 3-6 (Weeks 9-24- two weeks (days 1, 15 ) Consolidation- Every 4 weeks on day 1 Maintenance- Every 8 weeks on day 1
Study: NCT04140162
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 1-24)~Consolidation: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 25-36)~Maintenance: 10 mg PO once daily, on days 1-21 of each 28-day cycle until progression or intolerance~Maintenance: 10 mg PO once daily, on days 1-21, weeks 37+ until progression
Study: NCT04140162
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Consolidation: 1.5 mg/m2 SQ on day 1, 8, 15 and 22 of each 28-day cycle (weeks 25-36)
Study: NCT04140162
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction and Consolidation: 40 mg (or reduced dose of 20 mg) PO or IV weekly
Study: NCT01352416
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
Study: NCT03803982
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex will be used to reverse the deep neuromuscular blockade in the experimental group.
Study: NCT04083430
Drug: Yellow Fever Vaccine
Normalized name: yellow fever vaccine
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAMARIL, powder and solvent for suspension for injection in pre-filled syringe.~After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU.~Powder and solvent for suspension for injection.~Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution.